CN111228225B - Recombinant human tumor necrosis factor receptor-Fc fusion protein freeze-dried preparation - Google Patents
Recombinant human tumor necrosis factor receptor-Fc fusion protein freeze-dried preparation Download PDFInfo
- Publication number
- CN111228225B CN111228225B CN201811432448.5A CN201811432448A CN111228225B CN 111228225 B CN111228225 B CN 111228225B CN 201811432448 A CN201811432448 A CN 201811432448A CN 111228225 B CN111228225 B CN 111228225B
- Authority
- CN
- China
- Prior art keywords
- temperature
- drying
- freeze
- fusion protein
- recombinant human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 title claims abstract description 66
- 102000057041 human TNF Human genes 0.000 title claims abstract description 66
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 65
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 238000004108 freeze drying Methods 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 29
- 230000008569 process Effects 0.000 claims abstract description 26
- 150000001413 amino acids Chemical class 0.000 claims abstract description 7
- 239000004094 surface-active agent Substances 0.000 claims abstract description 6
- 239000000872 buffer Substances 0.000 claims abstract description 5
- 239000000945 filler Substances 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims description 69
- 238000007710 freezing Methods 0.000 claims description 54
- 230000008014 freezing Effects 0.000 claims description 54
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 36
- 239000007983 Tris buffer Substances 0.000 claims description 35
- 238000000859 sublimation Methods 0.000 claims description 33
- 230000008022 sublimation Effects 0.000 claims description 33
- 238000010438 heat treatment Methods 0.000 claims description 32
- 229930182555 Penicillin Natural products 0.000 claims description 19
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 19
- 229940049954 penicillin Drugs 0.000 claims description 19
- 238000001816 cooling Methods 0.000 claims description 17
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 15
- 238000005192 partition Methods 0.000 claims description 15
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 15
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 15
- 239000012460 protein solution Substances 0.000 claims description 15
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 12
- 229930006000 Sucrose Natural products 0.000 claims description 12
- 239000005720 sucrose Substances 0.000 claims description 12
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 7
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- 235000018417 cysteine Nutrition 0.000 claims description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
- 235000001014 amino acid Nutrition 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000012931 lyophilized formulation Substances 0.000 claims 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 abstract description 17
- 229940050526 hydroxyethylstarch Drugs 0.000 abstract description 17
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 238000003860 storage Methods 0.000 abstract description 7
- 239000000843 powder Substances 0.000 abstract description 4
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 229920001184 polypeptide Polymers 0.000 abstract description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 37
- 239000011265 semifinished product Substances 0.000 description 31
- 230000000052 comparative effect Effects 0.000 description 27
- 238000005303 weighing Methods 0.000 description 26
- 239000002158 endotoxin Substances 0.000 description 25
- 239000011550 stock solution Substances 0.000 description 19
- 239000007788 liquid Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000002156 mixing Methods 0.000 description 15
- 239000007853 buffer solution Substances 0.000 description 14
- 239000008215 water for injection Substances 0.000 description 14
- 239000012528 membrane Substances 0.000 description 13
- 238000011049 filling Methods 0.000 description 12
- 238000005070 sampling Methods 0.000 description 12
- 238000011146 sterile filtration Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108091005763 multidomain proteins Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 230000010512 thermal transition Effects 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention belongs to the technical field of protein and polypeptide medicines, and particularly relates to a recombinant human tumor necrosis factor receptor-Fc fusion protein freeze-dried powder preparation. The freeze-dried powder preparation comprises recombinant human tumor necrosis factor receptor-Fc fusion protein, amino acid, hydroxyethyl starch, a filler, a surfactant and a buffer. The recombinant human tumor necrosis factor receptor-Fc fusion protein obtained by freeze-drying through the formula and the freeze-drying process has high stability, is suitable for large-scale production, and is favorable for storage and transportation.
Description
Technical Field
The invention belongs to the technical field of protein and polypeptide medicines, and particularly relates to a recombinant human tumor necrosis factor receptor-Fc fusion protein freeze-dried powder preparation.
Background
Tumor Necrosis Factor (TNF) is a multifunctional cytokine, is closely related to various diseases and pathological reactions, plays a key role in autoimmune diseases such as inflammatory reaction, endotoxic shock, dyscrasia, rheumatoid arthritis and the like, and is one of the pathological mechanisms of various autoimmune diseases due to overexpression. Research on TNF receptors shows that the TNF receptors are widely distributed and have strong affinity with TNF. This soluble receptor neutralizes TNF and acts as a negative modulator of TNF activity in vivo. The extracellular region of the receptor is fused with the Fc segment gene of human immunoglobulin by using a receptor immunoglobulin fusion technology, and corresponding recombinant human tumor necrosis factor receptor (p75) -Fc fusion protein is expressed in vitro. It has the features of long in vivo half-life period, strong tissue penetrating power, etc. of immunoglobulin, and may be combined specifically with TNF to inhibit joint inflammation.
CN201480065341 discloses a liquid preparation of TNFR-Fc fusion protein, which comprises amino acids, a buffer solution and an isotonic agent, and although the stability of the TNFR-Fc fusion protein is improved to a certain extent, the phenomena of polymer content increase, activity reduction and the like can be caused after long-time storage.
CN201010613663 discloses a lyophilized powder for injection of recombinant human tumor necrosis factor receptor-Fc fusion protein, which contains sucrose, trehalose and other protective agents, and sodium acetate, tromethamine and other buffering agents, and the lyophilized recombinant human tumor necrosis factor receptor-Fc fusion protein has good stability, but the glass transition temperature of the protein still needs to be increased.
Since the freeze-drying process is a complex and variable process, there are many factors that affect the stability of proteins, thereby causing denaturation. The recombinant human tumor necrosis factor receptor-Fc fusion protein has a tendency of easy aggregation in the freeze-drying process, no matter what freeze-drying procedure, the pure protein is obviously damaged, and the problem to be solved is to select and add a proper protective agent to protect the activity of the recombinant human tumor necrosis factor receptor-Fc fusion protein.
Disclosure of Invention
The invention provides a freeze-dried preparation of recombinant human tumor necrosis factor receptor-Fc fusion protein, which has simple formula, stable protein system, convenient large-scale production, storage and transportation and convenient clinical administration. The inventor finds out a freeze-drying recombinant human tumor necrosis factor receptor-Fc fusion protein with a specific prescription by accident through a large number of creative experiments, develops a freeze-drying process suitable for the prescription, and the prepared recombinant human tumor necrosis factor receptor-Fc fusion protein preparation can improve the glass transition temperature of the protein and inhibit crystallization of various components in the freeze-drying process, thereby improving the stability of the recombinant human tumor necrosis factor receptor-Fc fusion protein.
The technical scheme adopted by the invention for solving the technical problems is as follows:
a freeze-dried preparation of recombinant human tumor necrosis factor receptor-Fc fusion protein comprises the recombinant human tumor necrosis factor receptor-Fc fusion protein, amino acid, hydroxyethyl starch, a filling agent, a surfactant and a buffer.
The amino acid is one or more of arginine, cysteine, threonine and lysine.
The bulking agent is selected from one or more of sucrose, trehalose, mannitol and sorbitol.
The surfactant is tween 20.
The buffer is Tris/HCl.
The recombinant human tumor necrosis factor receptor-Fc fusion protein freeze-dried preparation comprises the following components:
preferably, the lyophilized preparation of recombinant human tumor necrosis factor receptor-Fc fusion protein comprises the following components:
the recombinant human tumor necrosis factor receptor-Fc fusion protein is prepared into semi-finished product liquid by adopting the following process:
weighing a prescription amount of Tris, dissolving the Tris with a proper amount of water for injection, adjusting the pH with hydrochloric acid, sampling, detecting the qualified pH and endotoxin, accurately weighing the prescription amount of amino acid, a filling agent, hydroxyethyl starch, a surfactant and a recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution, adding the amino acid, the filling agent, the hydroxyethyl starch, the surfactant and the recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution into a Tris/HCl buffer solution, and uniformly mixing to obtain a semi-finished product solution; and (4) performing sterile filtration on the semi-finished product liquid by using a 0.22-micron filter membrane, and filling after detecting that the endotoxin is qualified.
A freeze-drying process of a recombinant human tumor necrosis factor receptor-Fc freeze-dried preparation adopts the following steps:
1) pre-freezing: pre-freezing the freeze-dried sample for 0.5-1h at 5 ℃, cooling to-60 ℃ to-40 ℃, keeping the temperature for 4-6h for freezing,
2) sublimation drying: maintaining the vacuum degree, setting the temperature to be between 25 ℃ below zero and 20 ℃ below zero for 10 hours, maintaining the vacuum degree for 20 to 30 hours,
3) and (3) drying again: maintaining the vacuum degree, heating to 30 deg.C, maintaining for 8-10h, resolving, drying, and lyophilizing.
Preferably, the freeze-drying process of the recombinant human tumor necrosis factor receptor-Fc freeze-dried preparation comprises the following steps:
1) pre-freezing: placing a penicillin bottle filled with a recombinant human tumor necrosis factor receptor-Fc fusion protein solution on a clapboard of a freeze dryer, pre-freezing at a set temperature of 5 ℃, keeping the preset temperature for 0.5-1h after setting for 10-30 min, cooling to-60-40 ℃, keeping the preset temperature for 5-10 min, and freezing for 4-6 h;
2) sublimation drying: heating the partition plate system to a set temperature of-25 ℃ to-20 ℃, keeping the temperature for 20-30h after 10h and keeping the vacuum degree for 0.2mBar, and finishing sublimation drying;
3) and (3) drying again: and (3) heating the temperature of the clapboard system to 30 ℃, setting the time to reach the preset temperature for 80-120 min, maintaining the drying time for 8-10h, maintaining the vacuum degree of 0.2mBar, and finishing the freeze-drying.
Compared with the prior art, the recombinant human tumor necrosis factor receptor-Fc fusion protein freeze-dried preparation has white and loose appearance, low product moisture content, quick redissolution, good stability and longer storage time, and is convenient for large-scale production, storage and transportation.
Detailed Description
The invention is further illustrated by the following examples. It should be properly understood that: the examples of the present invention are given solely for the purpose of illustration and not as limitations of the present invention, and therefore, simple modifications of the present invention in the context of the methods of the present invention are intended to fall within the scope of the claims.
Example 1
1) Prescription
2) The preparation process comprises the following steps: weighing a prescription amount of Tris, dissolving the Tris with a proper amount of water for injection, adjusting the pH to 8.0 by using hydrochloric acid, sampling, detecting the pH and detecting whether the endotoxin is qualified, accurately weighing the prescription amount of arginine, sucrose, hydroxyethyl starch, Tween 20 and recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution, adding the mixture into a Tris/HCl buffer solution, and uniformly mixing to obtain a semi-finished product solution; and (4) performing sterile filtration on the semi-finished product liquid by using a 0.22-micron filter membrane, and filling after detecting that the endotoxin is qualified.
3) And (3) freeze-drying process:
a) pre-freezing: placing a penicillin bottle filled with a recombinant human tumor necrosis factor receptor-Fc fusion protein solution on a clapboard of a freeze dryer, pre-freezing at a set temperature of 5 ℃, keeping for 1h after a set time of 30min reaches a preset temperature, cooling to-60 ℃, keeping for 6h after a set time of 10min reaches the preset temperature, and freezing;
b) sublimation drying: heating the partition plate system to-25 ℃ at a set temperature, maintaining the preset temperature for 10h, maintaining the preset temperature for 25h, and maintaining the vacuum degree for 0.2mBar to complete sublimation drying;
c) and (3) drying again: and (3) heating the temperature of the clapboard system to 30 ℃, setting the temperature for 100min to reach the preset temperature, maintaining the vacuum degree for 0.2mBar, and drying after 10 h.
Example 2
1) Prescription
2) The preparation process comprises the following steps: weighing a prescription amount of Tris, dissolving the Tris with a proper amount of water for injection, adjusting the pH to 7.0 by using hydrochloric acid, sampling, detecting the pH and detecting whether the endotoxin is qualified, accurately weighing the prescription amount of cysteine, trehalose, hydroxyethyl starch, Tween 20 and recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution, adding the prescription amount of cysteine, trehalose, hydroxyethyl starch, Tween 20 and recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution into a Tris/HCl buffer solution, and uniformly mixing to obtain a semi-finished product solution; and (4) performing sterile filtration on the semi-finished product liquid by using a 0.22-micron filter membrane, and filling after detecting that the endotoxin is qualified.
3) And (3) freeze-drying process:
a) pre-freezing: placing a penicillin bottle filled with a recombinant human tumor necrosis factor receptor-Fc fusion protein solution on a clapboard of a freeze dryer, pre-freezing at a set temperature of 5 ℃, keeping the temperature for 0.5h after setting for 10min, cooling to-40 ℃, keeping the temperature for 4h after setting for 5min, and freezing;
b) sublimation drying: heating the partition plate system to-20 ℃ at a set temperature, maintaining the preset temperature for 10h, maintaining the vacuum degree for 20h, and maintaining the vacuum degree for 0.2mBar to complete sublimation drying;
c) and (3) drying again: and (3) heating the temperature of the clapboard system to 30 ℃, setting the temperature for 80min to reach the preset temperature, maintaining the vacuum degree for 8h for drying, and simultaneously maintaining the vacuum degree for 0.2mBar, thus finishing the freeze-drying.
Example 3
1) Prescription
2) The preparation process comprises the following steps: weighing a prescription amount of Tris, dissolving the Tris with a proper amount of water for injection, adjusting the pH to 8.5 by using hydrochloric acid, sampling, detecting the pH and detecting whether the endotoxin is qualified, accurately weighing the prescription amount of threonine, cysteine, mannitol, hydroxyethyl starch, Tween 20 and recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution, adding the prescription amount of threonine, cysteine, mannitol, hydroxyethyl starch, Tween 20 and recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution into a Tris/HCl buffer solution, and uniformly mixing to obtain a semi-finished product solution; and (4) performing sterile filtration on the semi-finished product liquid by using a 0.22-micron filter membrane, and filling after detecting that the endotoxin is qualified.
3) And (3) freeze-drying process:
a) pre-freezing: placing a penicillin bottle filled with a recombinant human tumor necrosis factor receptor-Fc fusion protein solution on a clapboard of a freeze dryer, pre-freezing at a set temperature of 5 ℃, setting the temperature to reach the preset temperature for 30min, maintaining for 1h, cooling to-60 ℃, setting the temperature to reach the preset temperature for 10min, and maintaining for 6h for freezing;
b) sublimation drying: heating the partition plate system to-25 ℃ at a set temperature, maintaining the preset temperature for 10h, maintaining the vacuum degree for 30h, and maintaining the vacuum degree for 0.2mBar to complete sublimation drying;
c) and (3) drying again: and (3) heating the temperature of the clapboard system to 30 ℃, setting the temperature for 120min to reach the preset temperature, maintaining the vacuum degree for 0.2mBar, and drying after 10 h.
Example 4
1) Prescription
2) The preparation process comprises the following steps: weighing a prescription amount of Tris, dissolving the Tris with a proper amount of water for injection, adjusting the pH to 8.0 by using hydrochloric acid, sampling, detecting the qualified pH and endotoxin, accurately weighing the prescription amount of lysine, trehalose, sorbitol, hydroxyethyl starch, Tween 20 and recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution, adding the prescription amount of lysine, trehalose, sorbitol, hydroxyethyl starch, Tween 20 and recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution into a Tris/HCl buffer solution, and uniformly mixing to obtain a semi-finished product solution; and (4) performing sterile filtration on the semi-finished product liquid by using a 0.22-micron filter membrane, and filling after detecting that the endotoxin is qualified.
3) And (3) freeze-drying process:
a) pre-freezing: placing a penicillin bottle filled with a recombinant human tumor necrosis factor receptor-Fc fusion protein solution on a clapboard of a freeze dryer, pre-freezing at a set temperature of 5 ℃, keeping the temperature for 0.8h after setting for 20min, cooling to-50 ℃, keeping the temperature for 5h after setting for 8min, and freezing;
b) sublimation drying: heating the partition plate system to-25 ℃ at a set temperature, maintaining the preset temperature for 10h, maintaining the preset temperature for 25h, and maintaining the vacuum degree for 0.2mBar to complete sublimation drying;
c) and (3) drying again: and (3) heating the temperature of the clapboard system to 30 ℃, setting the temperature for 100min to reach the preset temperature, maintaining the vacuum degree for 9h for drying, and simultaneously maintaining the vacuum degree for 0.2mBar, thus finishing the freeze-drying.
Comparative example 1
1) Prescription
2) The preparation process comprises the following steps: accurately measuring proline, glutamic acid, histidine and recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution according to the prescription amount, adding the proline, the glutamic acid, the histidine and the recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution into a citrate-phosphate buffer solution with the pH value of 6.3, and uniformly mixing to obtain a semi-finished product solution; and (4) performing sterile filtration on the semi-finished product liquid by using a 0.22-micron filter membrane, and filling after detecting that the endotoxin is qualified.
3) And (3) a freeze-drying process:
a) pre-freezing: placing a penicillin bottle filled with a recombinant human tumor necrosis factor receptor-Fc fusion protein solution on a clapboard of a freeze dryer, pre-freezing at a set temperature of 5 ℃, keeping for 1h after a set time of 30min reaches a preset temperature, cooling to-60 ℃, keeping for 6h after a set time of 10min reaches the preset temperature, and freezing;
b) sublimation drying: heating the partition plate system to-25 ℃ at a set temperature, maintaining the preset temperature for 10h, maintaining the preset temperature for 25h, and maintaining the vacuum degree for 0.2mBar to complete sublimation drying;
c) and (3) drying again: and (3) heating the temperature of the clapboard system to 30 ℃, setting the temperature for 100min to reach the preset temperature, maintaining the vacuum degree for 0.2mBar, and drying after 10 h.
Comparative example 2
1) Prescription
2) The preparation process comprises the following steps:
accurately weighing according to the prescription, adding water for injection, mixing well, and adjusting pH to 7.30 with hydrochloric acid. The medicinal liquid is filtered by 0.22 μm filter disc made of polyvinylidene fluoride under pressure. To obtain the semi-finished product of the recombinant human tumor necrosis factor receptor-Fc fusion protein. And (3) subpackaging the semi-finished product into penicillin bottles (1 ml/bottle), putting the penicillin bottles into a freeze dryer, and starting the freeze dryer, wherein the process comprises the following steps:
a) a pre-freezing stage: the pre-freezing temperature is-38 ℃, and the pre-freezing temperature is kept for 3 hours;
b) a sublimation drying stage: the vacuum degree is 3bar, the temperature is-32 ℃, and the temperature is kept for 12 hours;
c) and (3) an analysis drying stage: drying at-20 deg.C, -10 deg.C, -5 deg.C, 10 deg.C, 20 deg.C, 30 deg.C for 2 hr to obtain recombinant human tumor necrosis factor receptor-Fc fusion protein powder for injection.
Comparative example 3
1) Prescription
2) The preparation process comprises the following steps:
accurately weighing according to the prescription, adding water for injection, mixing well, and adjusting pH to 7.30 with hydrochloric acid. The medicinal liquid is filtered by 0.22 μm filter disc made of polyvinylidene fluoride under pressure. To obtain the semi-finished product of the recombinant human tumor necrosis factor receptor-Fc fusion protein. And (3) subpackaging the semi-finished product into penicillin bottles (1 mL/bottle), putting the penicillin bottles into a freeze dryer, and starting the freeze dryer, wherein the process comprises the following steps:
a) pre-freezing: placing a penicillin bottle filled with a recombinant human tumor necrosis factor receptor-Fc fusion protein solution on a clapboard of a freeze dryer, pre-freezing at a set temperature of 5 ℃, keeping for 1h after a set time of 30min reaches a preset temperature, cooling to-60 ℃, keeping for 6h after a set time of 10min reaches the preset temperature, and freezing;
b) sublimation drying: heating the partition plate system to-25 ℃ at the set temperature, keeping the set temperature for 10h, keeping the set temperature for 25h, and keeping the vacuum degree for 0.2mBar to complete sublimation drying;
c) and (3) drying again: and (3) heating the temperature of the clapboard system to 30 ℃, setting the temperature for 100min to reach the preset temperature, maintaining the vacuum degree for 0.2mBar, and drying after 10 h.
Comparative example 4
1) Prescription
2) The preparation process comprises the following steps: weighing a prescription amount of Tris, dissolving the Tris with a proper amount of water for injection, adjusting the pH to 8.0 by using hydrochloric acid, sampling, detecting the qualified pH and endotoxin, accurately weighing the prescription amount of sucrose, hydroxyethyl starch, Tween 20 and recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution, adding the mixture into a Tris/HCl buffer solution, and uniformly mixing to obtain a semi-finished product solution; and (4) performing sterile filtration on the semi-finished product liquid by using a 0.22-micron filter membrane, and filling after detecting that the endotoxin is qualified.
3) And (3) freeze-drying process:
a) pre-freezing: placing a penicillin bottle filled with a recombinant human tumor necrosis factor receptor-Fc fusion protein solution on a clapboard of a freeze dryer, pre-freezing at a set temperature of 5 ℃, setting the temperature to reach the preset temperature for 30min, maintaining for 1h, cooling to-60 ℃, setting the temperature to reach the preset temperature for 10min, and maintaining for 6h for freezing;
b) sublimation drying: heating the partition plate system to-25 ℃ at a set temperature, maintaining the preset temperature for 10h, maintaining the preset temperature for 25h, and maintaining the vacuum degree for 0.2mBar to complete sublimation drying;
c) and (3) drying again: and (3) heating the temperature of the clapboard system to 30 ℃, setting the temperature for 100min to reach the preset temperature, maintaining the vacuum degree for 0.2mBar, and drying after 10 h.
Comparative example 5
1) Prescription
2) The preparation process comprises the following steps: weighing a prescription amount of Tris, dissolving the Tris with a proper amount of water for injection, adjusting the pH to 8.0 by using hydrochloric acid, sampling, detecting the qualified pH and endotoxin, accurately weighing the prescription amount of cysteine, sucrose, sorbitol, Tween 20 and recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution, adding the obtained solution into a Tris/HCl buffer solution, and uniformly mixing to obtain a semi-finished product solution; and (4) performing sterile filtration on the semi-finished product liquid by using a 0.22-micron filter membrane, and filling after detecting that the endotoxin is qualified.
3) And (3) freeze-drying process:
a) pre-freezing: placing a penicillin bottle filled with a recombinant human tumor necrosis factor receptor-Fc fusion protein solution on a clapboard of a freeze dryer, pre-freezing at a set temperature of 5 ℃, keeping for 1h after a set time of 30min reaches a preset temperature, cooling to-60 ℃, keeping for 6h after a set time of 10min reaches the preset temperature, and freezing;
b) sublimation drying: heating the partition plate system to-25 ℃ at a set temperature, maintaining the preset temperature for 10h, maintaining the preset temperature for 25h, and maintaining the vacuum degree for 0.2mBar to complete sublimation drying;
c) and (3) drying again: and (3) heating the temperature of the clapboard system to 30 ℃, setting the temperature for 100min to reach the preset temperature, maintaining the vacuum degree for 0.2mBar, and drying after 10 h.
Comparative example 6
1) Prescription
2) The preparation process comprises the following steps: weighing a prescription amount of Tris, dissolving the Tris with a proper amount of water for injection, adjusting the pH to 8.0, sampling, detecting the pH and qualified endotoxin, accurately weighing the prescription amount of arginine, sucrose, polyethylene glycol and recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution, adding the mixture into a Tris buffer solution, and uniformly mixing to obtain a semi-finished product solution; sterile filtering the semi-finished product liquid with 0.22 μm filter membrane, and packaging after endotoxin is detected to be qualified.
3) And (3) freeze-drying process:
a) pre-freezing: placing a penicillin bottle filled with a recombinant human tumor necrosis factor receptor-Fc fusion protein solution on a clapboard of a freeze dryer, pre-freezing at a set temperature of 5 ℃, keeping for 1h after a set time of 30min reaches a preset temperature, cooling to-60 ℃, keeping for 6h after a set time of 10min reaches the preset temperature, and freezing;
b) sublimation drying: heating the partition plate system to-25 ℃ at a set temperature, maintaining the preset temperature for 10h, maintaining the preset temperature for 25h, and maintaining the vacuum degree for 0.2mBar to complete sublimation drying;
c) and (3) drying again: and (3) heating the temperature of the clapboard system to 30 ℃, setting the temperature for 100min to reach the preset temperature, maintaining the vacuum degree for 0.2mBar, and drying after 10 h.
Comparative example 7
1) Prescription
2) The preparation process comprises the following steps: weighing disodium hydrogen phosphate and sodium dihydrogen phosphate according to a prescription amount, dissolving the disodium hydrogen phosphate and the sodium dihydrogen phosphate with a proper amount of water for injection, adjusting the pH to 6.0 by using hydrochloric acid, sampling and detecting the qualified pH and endotoxin, accurately weighing histidine, sucrose, hydroxyethyl starch, tween 20 and the recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution according to the prescription amount, adding the histidine, sucrose, hydroxyethyl starch, tween 20 and the recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution into a phosphoric acid buffer solution, and uniformly mixing to obtain a semi-finished product solution; and (4) performing sterile filtration on the semi-finished product liquid by using a 0.22-micron filter membrane, and filling after detecting that the endotoxin is qualified.
3) And (3) a freeze-drying process:
a) pre-freezing: placing a penicillin bottle filled with a recombinant human tumor necrosis factor receptor-Fc fusion protein solution on a clapboard of a freeze dryer, pre-freezing at a set temperature of 5 ℃, keeping for 1h after a set time of 30min reaches a preset temperature, cooling to-60 ℃, keeping for 6h after a set time of 10min reaches the preset temperature, and freezing;
b) sublimation drying: heating the partition plate system to-25 ℃ at a set temperature, maintaining the preset temperature for 10h, maintaining the preset temperature for 25h, and maintaining the vacuum degree for 0.2mBar to complete sublimation drying;
c) and (3) drying again: and (3) heating the temperature of the clapboard system to 30 ℃, setting the temperature for 100min to reach the preset temperature, maintaining the vacuum degree for 0.2mBar, and drying after 10 h.
Comparative example 8
1) Prescription
2) The preparation process comprises the following steps: weighing a prescription amount of Tris, dissolving the Tris with a proper amount of water for injection, adjusting the pH to 8.0 by using hydrochloric acid, sampling, detecting the qualified pH and endotoxin, accurately weighing the prescription amount of arginine, sucrose, hydroxyethyl starch and recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution, adding the mixture into a Tris/HCl buffer solution, and uniformly mixing to obtain a semi-finished product solution; and (4) performing sterile filtration on the semi-finished product liquid by using a 0.22-micron filter membrane, and filling after detecting that the endotoxin is qualified.
3) And (3) freeze-drying process:
a) pre-freezing: placing a penicillin bottle filled with a recombinant human tumor necrosis factor receptor-Fc fusion protein solution on a clapboard of a freeze dryer, pre-freezing at a set temperature of 5 ℃, keeping for 1h after a set time of 30min reaches a preset temperature, cooling to-60 ℃, keeping for 6h after a set time of 10min reaches the preset temperature, and freezing;
b) sublimation drying: heating the partition plate system to-25 ℃ at a set temperature, maintaining the preset temperature for 10h, maintaining the preset temperature for 25h, and maintaining the vacuum degree for 0.2mBar to complete sublimation drying;
c) and (3) drying again: and (3) heating the temperature of the clapboard system to 30 ℃, setting the temperature for 100min to reach the preset temperature, maintaining the vacuum degree for 0.2mBar, and drying after 10 h.
Comparative example 9
1) Prescription
2) The preparation process comprises the following steps: weighing a prescription amount of Tris, dissolving the Tris with a proper amount of water for injection, adjusting the pH to 8.0 by using hydrochloric acid, sampling, detecting the pH and detecting whether the endotoxin is qualified, accurately weighing the prescription amount of arginine, sucrose, hydroxyethyl starch, Tween 20 and recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution, adding the mixture into a Tris/HCl buffer solution, and uniformly mixing to obtain a semi-finished product solution; and (4) performing sterile filtration on the semi-finished product liquid by using a 0.22-micron filter membrane, and filling after detecting that the endotoxin is qualified.
3) And (3) a freeze-drying process:
a) pre-freezing: placing a penicillin bottle filled with a recombinant human tumor necrosis factor receptor-Fc fusion protein solution on a clapboard of a freeze dryer, pre-freezing at a set temperature of 5 ℃, keeping for 1h after a set time of 30min reaches a preset temperature, cooling to-60 ℃, keeping for 6h after a set time of 10min reaches the preset temperature, and freezing;
b) sublimation drying: heating the partition plate system to-25 ℃ at a set temperature, maintaining the preset temperature for 10h, maintaining the preset temperature for 25h, and maintaining the vacuum degree for 0.2mBar to complete sublimation drying;
c) and (3) drying again: and (3) heating the temperature of the clapboard system to 30 ℃, setting the temperature for 100min to reach the preset temperature, maintaining the vacuum degree for 10h for drying, and simultaneously maintaining the vacuum degree for 0.2mBar, thus finishing the freeze-drying.
Comparative example 10
1) Prescription
2) The preparation process comprises the following steps: weighing a prescription amount of Tris, dissolving the Tris with a proper amount of water for injection, adjusting the pH to 8.0 by using hydrochloric acid, sampling, detecting the pH and detecting whether the endotoxin is qualified, accurately weighing the prescription amount of arginine, sucrose, hydroxyethyl starch, Tween 20 and recombinant human tumor necrosis factor receptor-Fc fusion protein stock solution, adding the mixture into a Tris/HCl buffer solution, and uniformly mixing to obtain a semi-finished product solution; and (4) performing sterile filtration on the semi-finished product liquid by using a 0.22-micron filter membrane, and filling after detecting that the endotoxin is qualified.
3) And (3) freeze-drying process:
a) pre-freezing: placing a penicillin bottle filled with a recombinant human tumor necrosis factor receptor-Fc fusion protein solution on a clapboard of a freeze dryer, pre-freezing at a set temperature of 5 ℃, keeping for 1h after a set time of 10min reaches a preset temperature, cooling to-35 ℃, keeping for 2h after a set time of 10min reaches the preset temperature, and freezing;
b) sublimation drying: heating the partition plate system to-25 ℃ at a set temperature, maintaining the preset temperature for 10h, maintaining the vacuum degree for 0.2mBar, and completing sublimation drying;
c) and (3) drying again: and (3) heating the temperature of the clapboard system to 30 ℃, setting the temperature for 100min to reach the preset temperature, maintaining the vacuum degree for 5h for drying, and simultaneously maintaining the vacuum degree for 0.2mBar, thus finishing the freeze-drying.
Verification examples
1. Differential calorimetric scanning (DSC)
The melting temperatures T of the semi-finished solutions of the recombinant human TNF receptor-Fc fusion proteins of examples 1-4 and comparative examples 1-10 were determined using a MicroCalTM VP-Capillary DSC instrument at the instrument programmed temperature m The value is obtained. Diluting the sample with corresponding buffer solution until the concentration of the recombinant human tumor necrosis factor receptor-Fc fusion protein is 1mg/mL, adding 350 μ L of the sample into a sample well of a 96-well plate,and adding 350 mu L of corresponding buffer solution into the buffer hole, wherein the scanning temperature is set to be 20-90 ℃, and the scanning speed is 60 ℃/hr. Data analysis MicroCal VP-Capillary DSC automatic analysis software was used. The results are shown in Table 1.
TABLE 1T of recombinant human TNF receptor-Fc fusion protein m Value result
| Sample (I) | T m onset /℃ | T m1 /℃ | T m2 /℃ |
| Example 1 | 40.76 | 64.08 | 73.24 |
| Example 2 | 39.94 | 63.26 | 73.27 |
| Example 3 | 39.05 | 62.37 | 73.33 |
| Example 4 | 40.07 | 63.89 | 73.92 |
| Comparative example 1 | 30.37 | 56.69 | 72.92 |
| Comparative example 2 | 34.31 | 57.63 | 72.83 |
| Comparative example 3 | 34.31 | 57.63 | 73.53 |
| Comparative example 4 | 33.57 | 56.89 | 73.41 |
| Comparative example 5 | 32.06 | 55.38 | 73.53 |
| Comparative example 6 | 34.37 | 57.69 | 73.11 |
| Comparative example 7 | 36.41 | 59.73 | 73.14 |
| Comparative example 8 | 35.18 | 58.5 | 73.2 |
| Comparative example 9 | 36.69 | 60.01 | 73.79 |
| Comparative example 10 | 36.15 | 59.47 | 72.79 |
T m The value represents the midpoint temperature of the thermal transition of the protein, and there may be multiple Ts for a multidomain protein m The value, which is an important indicator of the thermal stability of a protein, the upward shift representing an increase in stability, can be used to assess the tendency of oligomers and aggregates to form. T is m onset Is the temperature at which unfolding starts, T m1 Is the first transition temperature, T m2 Is the second transition temperature. Comparative examples 1-3 are prior art formulations and the results in Table 1 show the highest T of the prior art m onset About 34.31 ℃ and T of the invention m onset The maximum temperature can reach 40.76 ℃, and is improved by 6.45 ℃ compared with the prior art. Comparative examples 4 to 10 all compare T of the present invention after changing the prescription m onset Low.
2. Stability test
Three batches of samples were prepared according to examples 1-4 and comparative examples 1-10, respectively, and 60 bottles were taken from each batch, and the storage stability was examined using accelerated stability tests and long-term tests.
The accelerated test was carried out at 25 ℃. + -. 2 ℃ for 12 months. The used equipment can control the temperature to +/-2 ℃ and monitor the actual temperature. Samples were taken at the end of 0, 3, 6, and 12 months during the test period and examined according to stability stress. The long-term test is carried out at the temperature of 2-8 ℃, and the long-term test is carried out according to stability key examination items at the end of 0 month, 3 months, 6 months, 12 months and 24 months respectively; (the water content is measured by a Mettler-Zaliduo DL37 Karl Fischer titrator according to the coulomb method specified in the third general rule of 2015 edition of Chinese pharmacopoeia, and the purity is measured by a general rule 0514 molecular array chromatography and a general rule 0542 capillary electrophoresis), the result shows that no significant change exists in comparison with 0 month, the comparison ratio has more stable characteristics, and the result is shown in tables 2 and 3.
TABLE 2.2-8 deg.C long-term stability test results
TABLE 3.25 ℃ accelerated stability test results
The stability data results in tables 2 and 3 show that the lyophilized formulations of examples 1-4 are white loose bodies, clear and transparent after reconstitution, and slightly opalescent; the water content is less than 1.00%; the monomer content is not less than 98.6 percent after being stored for 24 months at the temperature of 2-8 ℃; the monomer content can still reach the effect of ≧ 95% when the product is stored for 12 months at 25 ℃. In the prior art, after the comparative examples 1 to 3 are stored at 2 to 8 ℃ for 24 months, the monomer contents are respectively 87.9%, 98.1% and 97.9%, and the monomer contents are respectively 86.7%, 93.5% and 92.0% after the comparative examples are stored at 25 ℃ for 12 months, the storage time under the accelerated experiment condition is far shorter than that of the invention, and the stability of the freeze-dried preparation is also far shorter than that of the invention after the formula freeze-drying process is changed compared with the comparative examples 4 to 10.
Claims (4)
1. A freeze-dried preparation of recombinant human tumor necrosis factor receptor-Fc fusion protein is characterized in that the freeze-dried preparation consists of the following components:
wherein the amino acid is one or more of arginine, cysteine, threonine and lysine; the buffer is Tris/HCl; the filler is one or more of sucrose, trehalose, mannitol and sorbitol; the surfactant is tween 20.
2. The lyophilized formulation of recombinant human tumor necrosis factor receptor-Fc fusion protein according to claim 1, wherein said lyophilized formulation comprises the following components:
3. a freeze-drying process of the recombinant human tumor necrosis factor receptor-Fc fusion protein freeze-dried preparation according to any one of claims 1-2, characterized in that the freeze-drying is carried out by adopting the following steps:
1) pre-freezing: pre-freezing the freeze-dried sample for 0.5-1h at 5 ℃, cooling to-60 ℃ to-40 ℃, keeping for 4-6h for freezing,
2) sublimation drying: maintaining the vacuum degree, setting the temperature to be between 25 ℃ below zero and 20 ℃ below zero for 10 hours, maintaining the temperature for 20 to 30 hours,
3) and (3) drying again: maintaining the vacuum degree, heating to 30 deg.C, maintaining for 8-10h, resolving, drying, and lyophilizing.
4. The process for lyophilizing a lyophilized preparation of recombinant human TNF-Fc fusion protein according to claim 3, wherein the lyophilization is carried out by the following steps:
1) pre-freezing: placing a penicillin bottle filled with a recombinant human tumor necrosis factor receptor-Fc fusion protein solution on a clapboard of a freeze dryer, pre-freezing at a set temperature of 5 ℃, keeping the preset temperature for 0.5-1h after setting for 10-30 min, cooling to-60 ℃ to-40 ℃, keeping the preset temperature for 5-10 min, and freezing for 4-6 h;
2) sublimation drying: heating the partition plate system to a set temperature of minus 25 ℃ to minus 20 ℃, keeping the temperature for 20-30h after a set time of 10h is up to the set temperature, and simultaneously keeping the vacuum degree of 0.2mBar, thereby completing sublimation drying;
3) and (3) drying again: and (3) heating the temperature of the clapboard system to 30 ℃, setting the time for 80-120 min to reach the preset temperature, maintaining for 8-10h for drying, maintaining the vacuum degree of 0.2mBar, and finishing the freeze-drying.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811432448.5A CN111228225B (en) | 2018-11-28 | 2018-11-28 | Recombinant human tumor necrosis factor receptor-Fc fusion protein freeze-dried preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811432448.5A CN111228225B (en) | 2018-11-28 | 2018-11-28 | Recombinant human tumor necrosis factor receptor-Fc fusion protein freeze-dried preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111228225A CN111228225A (en) | 2020-06-05 |
| CN111228225B true CN111228225B (en) | 2022-08-26 |
Family
ID=70875656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811432448.5A Active CN111228225B (en) | 2018-11-28 | 2018-11-28 | Recombinant human tumor necrosis factor receptor-Fc fusion protein freeze-dried preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111228225B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114015758B (en) * | 2021-10-15 | 2022-06-24 | 无锡百泰克生物技术有限公司 | Freeze-drying protective agent, fluorescent PCR detection kit and freeze-drying process |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106729633A (en) * | 2017-03-03 | 2017-05-31 | 上海唯科生物制药有限公司 | A kind of TNF rectally preparation and preparation method thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1946776B1 (en) * | 2002-02-27 | 2017-01-18 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| CN1246337C (en) * | 2002-11-26 | 2006-03-22 | 广州绿阳生物工程有限公司 | Novel TNFR-Fc fusion protein |
| SG10201604258YA (en) * | 2007-11-30 | 2016-07-28 | Abbvie Biotechnology Ltd | Anti-tnf antibody formulations |
| AU2009333791B2 (en) * | 2008-10-29 | 2013-04-04 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
| CN101747440B (en) * | 2008-12-18 | 2014-05-07 | 嘉和生物药业有限公司 | TNFR-Fc fusion protein and usage thereof |
| CN102946858B (en) * | 2010-05-10 | 2015-09-30 | 英塔斯制药有限公司 | The liquid preparation of the polypeptide containing immunoglobulin Fc |
| CN102068696B (en) * | 2010-12-30 | 2012-07-11 | 山东新时代药业有限公司 | Freeze-dried powder injection with recombinant human tumor necrosis factor receptor (TNFR)-Fc fusion protein |
| KR101673654B1 (en) * | 2011-04-20 | 2016-11-07 | 산도즈 아게 | STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc |
| CN113244374A (en) * | 2011-07-01 | 2021-08-13 | 生物基因Ma公司 | Arginine-free TNFR-FC-fusion polypeptide compositions and methods of use |
| AR088460A1 (en) * | 2011-10-18 | 2014-06-11 | Coherus Biosciences Inc | FORMULATIONS OF ETANERCEPT STABILIZED WITH AMINO ACIDS |
| CN108771655A (en) * | 2011-10-28 | 2018-11-09 | 诚信生物公司 | Protein formulation containing amino acid |
| AU2014354384B2 (en) * | 2013-11-29 | 2018-11-08 | Ares Trading S.A. | A liquid formulation of a fusion protein comprising TNFR and Fc region |
| CN104740612A (en) * | 2013-12-31 | 2015-07-01 | 上海中信国健药业股份有限公司 | Liquid formulation of receptor antibody fusion protein |
| CN103920148B (en) * | 2014-04-24 | 2016-06-22 | 山东新华医疗器械股份有限公司 | A kind of freeze drying process of monoclonal antibody formulation |
| JP6480154B2 (en) * | 2014-11-06 | 2019-03-06 | 持田製薬株式会社 | Lyophilized formulation of etanercept |
-
2018
- 2018-11-28 CN CN201811432448.5A patent/CN111228225B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106729633A (en) * | 2017-03-03 | 2017-05-31 | 上海唯科生物制药有限公司 | A kind of TNF rectally preparation and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111228225A (en) | 2020-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0732935B1 (en) | Lyophilized stem cell factor formulations | |
| EP3199555B1 (en) | Recombinant fusion protein formulation | |
| US11273205B2 (en) | IL-15 protein complex pharmaceutical composition | |
| CN111228225B (en) | Recombinant human tumor necrosis factor receptor-Fc fusion protein freeze-dried preparation | |
| JP3714951B2 (en) | IL-6-containing pharmaceutical composition | |
| CN101693016B (en) | Universal pharmaceutical formulation for recombined human serum albumin fusion proteins for injection | |
| CN103076213B (en) | Preparation method of glycosylated albumin quality control | |
| JPH03505334A (en) | Lyophilized peptide formulation | |
| CN108379561B (en) | Pegylated urate oxidase freeze-dried powder and preparation method thereof | |
| WO2020003139A2 (en) | Stable lyophilized dosage form of protein | |
| AU2025205577A1 (en) | Pharmaceutical compositions for treating acid sphingomyelinase deficiency | |
| CN103736078B (en) | Polypeptide lyophilized powder injection preparations of mPEG HM 3 and its production and use | |
| CN113117071B (en) | Freeze-dried preparation of non-glycosylated anti-PD-1 monoclonal antibody | |
| US20240100158A1 (en) | Freeze dried antibody formulations and methods thereof | |
| CN114224851A (en) | A kind of lyophilized powder preparation of human interleukin 10-Fc fusion protein and preparation method | |
| CN116077649A (en) | Freeze-dried preparation containing anti-Blys monoclonal antibody and preparation process thereof | |
| CN111195234B (en) | Recombinant FGF21-Fc fusion protein freeze-dried powder preparation | |
| CN117820457A (en) | Cytokine freeze-drying protective agent and application thereof, and preparation method of cytokine freeze-dried product | |
| CN112137967B (en) | Recombinant human FGF21-Fc fusion protein freeze-dried preparation | |
| CN115581674A (en) | PD-L1/TGF beta combined bifunctional antibody fusion protein freeze-dried preparation | |
| CN111375052A (en) | Freeze-drying method of freeze-dried preparation of azadirachtin for injection | |
| US20250302919A1 (en) | Pharmaceutical compositions of efruxifermin | |
| CN111686079A (en) | Follicle stimulating hormone freeze-dried preparation and preparation method and application thereof | |
| CN115656496A (en) | A kind of universal freeze-drying protectant and its application | |
| CN115944724A (en) | Lyophilized powder preparation of recombinant humanized anti-CD 19/CD3 bispecific antibody for injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |